Research from Sichuan University Yields New Data on Psoriasis (Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report).

A recent study conducted by researchers at Sichuan University in Chengdu, China, explored the treatment of acrodermatitis continua of Hallopeau (ACH) coexisting with generalized pustular psoriasis (GPP) using spesolimab. GPP is a rare chronic inflammatory pustular dermatosis, and ACH is a variant of pustular psoriasis characterized by sterile pustules on the fingers and toes. The researchers found that spesolimab, an anti-interleukin-36 receptor biologic, showed promising results in treating ACH and GPP. The study reported a case of an Asian patient with a 16-year history of GPP and ACH who experienced skin clearance and resolution of nail lesions after receiving spesolimab in combination with secukinumab. This research suggests that spesolimab may be an effective treatment for ACH, particularly in patients with intractable nail lesions and concomitant GPP. [Extracted from the article]